Diabetic Gastroparesis Market Size, Share & Industry Analysis, By Types (Grade 2 (Compensated Gastroparesis), Grade 3 (Gastric Failure)), By Treatment (Pharmacological Treatment, Surgery), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And Regional Forecast, 2024-2032

Gastroparesis is a medical condition that disturbs the natural movement of the muscles of the stomach, leading to the slow or stationary motility of the stomach and preventing it from emptying. Gastroparesis can damage the vagus nerve which regulates the metabolic system and may result in nausea, vomiting and can also affect blood sugar levels. The categories of gastroparesis include diabetic, idiopathic, and post-surgical gastroparesis. Among them, diabetic gastroparesis is considered one of the most common forms. The increased R&D by manufacturers for the treatment of this disease is expected to drive the market.

The increase in incidences and prevalence of diabetes is the primary factor for the growth of this market. World Health Organization estimated that 422 million people were diagnosed with diabetes in 2016 and one of the leading causes of death in the world. Moreover, according to the American Diabetes Association 2019, gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, and the number of patients with gastroparesis could potentially be parallel to millions. In addition to that, an increase in the geriatric population around the world, sedentary lifestyles have led to an increasing incidence of diabetic cases. Furthermore, continuous efforts by manufacturers for the more advanced drug for the treatment of gastroparesis will also drive the market growth.

However, stringent guidelines for the approval of novel drugs and the lack of awareness about gastroparesis among the populace are likely to restrict the growth of the market.

Market Segmentation:

The global diabetic gastroparesis market can be segmented on the basis of types, treatment, end-users, and region. Based on the type, the market can be segmented into, grade 2 (compensated gastroparesis), and grade 3 (gastric failure). Based on the treatment, the market can be segmented into pharmacological treatment and surgery. The pharmacological treatment segment can further be segmented into prokinetics, antiemetic agents, botulinum toxin, and others. Based on the distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Geographically, the diabetic gastroparesis market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Key Players Covered:

The major companies in the global diabetic gastroparesis report include Theravance Biopharma., Abbott, Allergan, AstraZeneca, Cadila Pharmaceuticals., Evoke Pharma, Neurogastrx, Inc, Bausch Health. Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and other prominent players.

Key Insights:

• Key Industry Developments - Mergers, Acquisitions, and Partnerships


• Prevalence of Gastroparesis


• Pipeline Analysis


• Recent Diabetic gastroparesis Research & Development Activities

Regional Analysis:

Geographically, the global diabetic gastroparesis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia-Pacific region is at the forefront of the current epidemic of diabetes and this region is expected to dominate the global diabetic gastroparesis market and follow the same trend during the forecast period. Moreover, the geriatric population in the Asia Pacific region is quite higher than any other area worldwide and diabetic neuropathy is leading to an increase in incidences of diabetic gastroparesis. North America is projected to hold the second-largest share of the market, followed by Europe. The growth in this region can be attributed to an increase in diabetes patients and high awareness regarding gastroparesis treatment.

Segmentation

Diabetic Gastroparesis Market Industry Developments

• In June, 2019 Theravance Biopharma reported that Velusetrag, an oral, highly selective 5-hydroxytryptamine receptor 4 agonist, effectively reduced symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis.


• In January 2018, Neurogastrx, Inc. announced fund raising USD 45Mn co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. The funds will allow the company to fill out the management team and reach proof of concept with its lead asset, NG-101, which is intended to treat gastroparesis, a debilitating functional GI disorder.